<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584711</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 1605</org_study_id>
    <nct_id>NCT03584711</nct_id>
  </id_info>
  <brief_title>FOLFOX + Panitumumab According to a &quot;Stop and go&quot; Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation</brief_title>
  <acronym>OPTIPRIME</acronym>
  <official_title>A Phase II Study Evaluating FOLFOX + Panitumumab According to a &quot;Stop and go&quot; Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm, multi-centre phase II study The primary objective is to evaluate the time to
      failure of the strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the OPTIPRIME phase II non-randomised study is to evaluate the efficacy and
      tolerability of the combination of FOLFOX plus panitumumab according to a &quot;stop and go&quot;
      strategy. If disease control is achieved while on induction treatment, oxaliplatin and
      panitumumab will be stopped after the sixth cycle; a maintenance treatment of
      fluoropyrimidine alone will be continued. In case of progression during maintenance
      treatment, oxaliplatin and panitumumab reintroduction loops will take place according to the
      same regimen (maintenance treatment after six cycles of the reintroduced therapy if disease
      control is achieved).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to failure of the strategy</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Time to strategy Failure is defined as the time from date of inclusion to strategy failure (Radiological progression under treatment or death or definitive treatment discontinuation or recurrence after curative surgery with or without adjuvant treatment)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours
LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>FOLFOX + panitumumab</intervention_name>
    <description>FOLFOX + panitumumab according to a &quot;stop and go&quot; strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment</description>
    <arm_group_label>FOLFOX + panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Histologically proven colorectal adenocarcinoma without RAS mutation

          -  Confirmed, non-resectable metastatic disease (Stage IV)

          -  No prior chemotherapy except perioperative or adjuvant chemotherapy discontinued for
             more than 12 months

          -  At least one measurable metastasis according to the RECIST v1.1 criteria

          -  Age ≥ 18 years

          -  WHO ≤ 2

          -  Neutrophils &gt; 1500 /mm3, platelets&gt; 100 000/mm3, Hb &gt; 9 g/dL

          -  Creatinine clearance &gt; 50 mL/min according to the MDRD formula

          -  Serum bilirubin &lt; 25 µmol/L, AST, ALT, Alk Phos &lt; 2.5 x ULN or &lt; 5 x ULN in case of
             liver metastases

          -  PT &gt; 60%, albumin ≥ 25g/L

          -  Estimated life expectancy ≥ 3 months

          -  Patient affiliated to a social security scheme

          -  Patient informed and informed consent form signed

        Exclusion Criteria:

          -  - Presence of uncontrolled symptomatic brain metastases

          -  RAS mutation (KRAS or NRAS mutation)

          -  Patient taking warfarin. If treated with anticoagulant at the indicated effective
             dose, this must be replaced with low molecular weight heparin before inclusion

          -  Known DPD deficiency

          -  Peripheral neuropathy &gt; 1 (NCI CTCAE v4.0)

          -  Patient with interstitial pneumonitis or pulmonary fibrosis

          -  History of chronic diarrhoea or inflammatory disease of the colon or rectum, or
             obstruction or sub-obstruction during symptomatic treatment

          -  Poorly controlled chronic skin disease

          -  Any known specific contraindication or allergy to the medicinal products used in the
             study

          -  Patient simultaneously included in another clinical trial involving an investigational
             drug (example: chemotherapy, targeted therapy, immunotherapy)

          -  Arterial hypertension not controlled by medical treatment (Systolic BP ≥ 160 mmHg
             end/or diastolic BP ≥ 90 mmHg)

          -  Any progressive pathology not stabilised over the past 6 months: hepatic failure,
             renal failure, respiratory failure

          -  The following conditions in the 6 months prior to inclusion: myocardial infarction,
             severe/unstable angina, coronary artery bypass surgery, congestive heart failure NYHA
             class II, III or IV, stroke or transient ischaemic attack

          -  Patient who has received a transplant, is seropositive for HIV, hepatitis B or
             hepatitis C or has other immunodeficiency syndromes

          -  History of malignant pathologies during the past 5 years except basal cell carcinoma
             of the skin or cervical carcinoma in situ, properly treated

          -  QT/QTc interval &gt; 450 msec for men and &gt; 470 msec for women

          -  K+ &lt; LNL, Mg2+ &lt; LNL, Ca2+ &lt; LNL

          -  Lack of effective contraception in patients (men and/or women) of childbearing age,
             pregnant or breastfeeding women, women of childbearing age who have not had a
             pregnancy test

          -  Persons in custody or under wardship

          -  Impossibility of undergoing medical monitoring during the trial for geographical,
             social or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste Bachet, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federation Francophone de Cancerologie Digestive</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lila gaba</last_name>
    <phone>0380393483</phone>
    <email>lila.gaba@u-bourgogne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jeremie bez</last_name>
    <phone>0380393483</phone>
    <email>jeremie.bez@u-bourgogne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Trenel</name>
      <address>
        <city>Sainte Colombe</city>
        <state>Lyon</state>
        <zip>69560</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan GRABER, Dr</last_name>
      <email>graber.trenel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Berge, Dr</last_name>
      <email>berge@claude-bernard-albi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent HAUTEFEUILLE, Dr</last_name>
      <email>hautefeuille.vincent@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de L'Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Gozy, Dr</last_name>
      <email>michelgozy@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu D'Angers</name>
      <address>
        <city>Angers CEDEX 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole VITELLIUS, Dr</last_name>
      <email>carole.vitellius@chu-angers.fr; carole.vitellius@wanadoo.fr; cvitellius@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Prive D'Antony</name>
      <address>
        <city>Antony</city>
        <zip>92166</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne THIROT BIDAULT, Dr</last_name>
      <email>a.t.bidault@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Les Bonnettes</name>
      <address>
        <city>Arras CEDEX</city>
        <zip>62012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno HUGUENIN, Dr</last_name>
      <email>drbhuguenin@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Marie Curie</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie BLANC-GUERINEAU</last_name>
      <email>drblanc@radiopole-artois.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Cote Basque</name>
      <address>
        <city>Bayonne CEDEX</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck AUDEMAR, Dr</last_name>
      <email>faudemar@ch-cotebasque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fayçal HOCINE, Dr</last_name>
      <email>f.hocine@ch-beauvais.fr ; fayoncologie@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint Privat</name>
      <address>
        <city>Boujan-sur-Libron</city>
        <zip>34760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaël HUMMELSBERGER, Dr</last_name>
      <email>michael.hummelsberger@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cmco Cote D'Opale</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <zip>62222</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GASNAULT, Dr</last_name>
      <email>laurent.gasnault@sfr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Duchenne</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent BOURGEOIS, Dr</last_name>
      <email>vincebourgeois@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Morvan - Chu</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe METGES, Dr</last_name>
      <email>jean-philippe.metges@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Beziers Cedex</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed RAMDANI, Dr</last_name>
      <email>mohamed.ramdani@ch-beziers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CORBINAIS, Dr</last_name>
      <email>s.corbinais@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Cahors</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia LEVASSEUR, Dr</last_name>
      <email>nadia.levasseur@ch-cahors.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49325</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique ALABERT, Dr</last_name>
      <email>frederique.alabert@ch-cholet.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General</name>
      <address>
        <city>Châlons-en-Champagne</city>
        <zip>51005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROCH ANICET OSSENDZA, Dr</last_name>
      <email>rochossendza@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BREYSACHER, Dr</last_name>
      <email>gilles.breysacher@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Medecine</name>
      <address>
        <city>Digne-les-Bains</city>
        <zip>04000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert BORDES, Dr</last_name>
      <email>gbordes@ch-digne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Dunkerque CEDEX 01</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana CEBAN RUDIC, Dr</last_name>
      <email>tatiana.ceban@ch-dunkerque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Jacques Monod</name>
      <address>
        <city>Flers CEDEX</city>
        <zip>61104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Emmanuel HENNERESSE, Dr</last_name>
      <email>pierre-emmanuel.henneresse@ch-flers.fr ; netpeh@orange.fr; p.e.henneresse@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi de Frejus Saint-Raphael</name>
      <address>
        <city>Fréjus</city>
        <zip>83600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno VALENZA, Dr</last_name>
      <email>valenza-b@chi-frejus-saint-raphael.fr;oncologie-sec@chi-fsr.fr; brunovalenza@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Blois - 3Eme Etage</name>
      <address>
        <city>La Chaussee St Victor</city>
        <zip>41260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe LAPLAIGE, Dr</last_name>
      <email>dr.laplaige@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger FAROUX, Dr</last_name>
      <email>roger.faroux@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Du Mans</name>
      <address>
        <city>Le Mans CEDEX 9</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oana COJOCARASU, Dr</last_name>
      <email>ocojocarasu@ch-lemans.fr; oanaalexa@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice PHAM-BECKER, Dr</last_name>
      <email>apham@ch-lens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Hopital Claude Huriez 4Eme Est</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony TURPIN, Dr</last_name>
      <email>turpin.anth@yahoo.fr; anthony.turpin@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch St Joseph-St Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69365</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis PERE VERGE, Dr</last_name>
      <email>dpereverge@ch-stjoseph-stluc-lyon.fr; fannydenis@sfr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13331</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves RINALDI, Dr</last_name>
      <email>y.rinaldi@hopital-europeen.fr; yrinaldi@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LOCHER, Dr</last_name>
      <email>c-locher@ch-meaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Layne</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DAUBA, Dr</last_name>
      <email>jerome.dauba@ch-mt-marsan.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien BROCARD, Dr</last_name>
      <email>f.brocard@oncog.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Du Confluent Sas</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin LINOT, Dr</last_name>
      <email>benjamin.linot@groupeconfluent.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Niort - Sce D'Oncologie</name>
      <address>
        <city>Niort CEDEX</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert ALEBA, Dr</last_name>
      <email>albert.aleba@ch-niort.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris CEDEX 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste BACHET, Dr</last_name>
      <email>jean-baptiste.bachet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORIAT, Pr</last_name>
      <email>romain.coriat@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Bachet, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karinne PRULHIER-CORVIOLE, Dr</last_name>
      <email>kpulhiere@iccreims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saint-Quentin CEDEX</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Innocenti DADAMESSI, Dr</last_name>
      <email>I.dadamessi@ch-stquentin.fr;dadamessi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Ste Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis-Marie DOURTHE, Dr</last_name>
      <email>lm.dourthe@solcrr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher BEN ABDELGHANI, Dr</last_name>
      <email>mbenabdelghani@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de L'Ormeau</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe AYELA, Dr</last_name>
      <email>Payela@ch-lourdes.fr ; philippe.ayela@sfr.fr ; nathaliemonteiro@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde MARTINEZ, Dr</last_name>
      <email>m.martinez@clinique-pasteur.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Fort de France</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie GROSSAT BERNADOU, Dr</last_name>
      <email>nathalie.grossat-bernadou@chu-martinique.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stop and Go strategy</keyword>
  <keyword>RAS Wild-type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

